Pfizer's mRNA flu shot outperforms standard flu vaccine in late-stage trial
Pfizer's mRNA flu shot outperforms standard flu vaccine in late-stage trial
www.nbcnews.com
Pfizer's mRNA flu shot outperforms standard flu vaccine in late-stage trial
The Phase 3 trial found Pfizer’s mRNA shot cut flu-like illness by 34.5% compared with a standard flu shot.
